Big data reveals Real-World costs and dosing for SMA therapies
NCT ID NCT07378943
First seen Feb 01, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study analyzed insurance claims from over 4,000 people with spinal muscular atrophy to see how three approved drugs (Zolgensma, Spinraza, and Evrysdi) are actually used in practice and what they cost. Researchers looked at dosing patterns, yearly costs, and overall healthcare expenses from 2016 to 2024. The goal was to understand real-world treatment patterns, not to test new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.